Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007340
Chunk: 116

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 116
---
center'>PLAN OF DISTRIBUTION</div>

Each selling shareholder and
any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their Ordinary Shares represented
by Depositary Shares covered by this prospectus on the principal trading market or any other stock exchange, market or trading facility
on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A selling shareholder
may use any one or more of the following methods when selling securities:

| · | ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; |

| · | block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the 
 block as principal to facilitate the transaction;                                                                                 |

| · | purchases by a broker-dealer as principal and resale by the broker-dealer for its account; |

| · | an exchange distribution in accordance with the rules of the applicable exchange; |

| · | privately negotiated transactions; |

| · | settlement of short sales; |

| · | in transactions through broker-dealers that agree with the selling shareholders to sell a specified number of such securities at a 
 stipulated price per security;                                                                                                     |

| · | through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; |

| · | a combination of any such methods of sale; or |

| · | any other method permitted pursuant to applicable law. |

The selling shareholders may
also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under
this prospectus.

Broker-dealers engaged by
the selling shareholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from the selling shareholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts
to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a
customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in
compliance with FINRA IM-2440.

In connection with the sale
of the securities or interests therein, the selling shareholders may enter into hedging transactions with broker-dealers or other financial
institutions, which may in turn engage in short sales